Literature DB >> 16304505

Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use.

Simon C Burton1.   

Abstract

Despite the advances in the treatment of patients with schizophrenia that have occurred since the introduction of the second-generation (atypical) antipsychotic agents, a leading cause of suboptimal outcome is poor patient adherence to oral medication. Partial adherence can be attributed to a number of factors, including lack of insight, cognitive dysfunction, a complicated treatment regimen, drug-related side effects, patient attitude, lack of patient education, and cultural factors. A number of strategies, including psychosocial interventions, cognitive-behavioral techniques, strategies that minimize side effects, and pharmacological approaches that increase ease of medication use, can be employed to support adherence and improve long-term outcomes. This article focuses on strategies for increasing ease of use of antipsychotics in the treatment of patients with schizophrenia. These strategies include using monotherapy rather than polypharmacy, simplifying the medication regimen, and using a long-acting antipsychotic formulation. The goal of these strategies is to improve adherence and help prevent relapse by ensuring continuous antipsychotic coverage. Strategies that optimize ease of use of medication treatment for schizophrenia and thus improve adherence to treatment are likely to promote the attainment of new treatment goals and improved patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304505     DOI: 10.1097/00131746-200511000-00003

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  24 in total

1.  Evaluating appropriateness of prescribing of long-acting risperidone for injection in acute care settings.

Authors:  Greg T Mah; Jane Dumontet; Anisha Lakhani; Susan Corrigan
Journal:  Can J Hosp Pharm       Date:  2010-11

Review 2.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

3.  Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.

Authors:  Anne Schmechtig; Jane Lees; Lois Grayson; Kevin J Craig; Rukiya Dadhiwala; Gerard R Dawson; J F William Deakin; Colin T Dourish; Ivan Koychev; Katrina McMullen; Ellen M Migo; Charlotte Perry; Lawrence Wilkinson; Robin Morris; Steve C R Williams; Ulrich Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2013-02-22       Impact factor: 4.530

Review 4.  Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments.

Authors:  Michael W Jann
Journal:  Am Health Drug Benefits       Date:  2014-12

5.  The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia.

Authors:  Marcela Horvitz-Lennon; Margarita Alegría; Sharon-Lise T Normand
Journal:  Psychiatr Serv       Date:  2012-12       Impact factor: 3.084

6.  Life and treatment goals of individuals hospitalized for first-episode nonaffective psychosis.

Authors:  Claire E Ramsay; Beth Broussard; Sandra M Goulding; Sarah Cristofaro; Dustin Hall; Nadine J Kaslow; Eóin Killackey; David Penn; Michael T Compton
Journal:  Psychiatry Res       Date:  2011-06-25       Impact factor: 3.222

Review 7.  Pharmacological approaches to the management of cognitive dysfunction in schizophrenia.

Authors:  Philip D Harvey; Margaret M McClure
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder.

Authors:  Margaret M McClure; Harold W Koenigsberg; Diedre Reynolds; Marianne Goodman; Antonia New; Robert Trestman; Jeremy Silverman; Philip D Harvey; Larry J Siever
Journal:  J Clin Psychopharmacol       Date:  2009-08       Impact factor: 3.153

9.  Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum.

Authors:  Margaret M McClure; Philip D Harvey; Marianne Goodman; Joseph Triebwasser; Antonia New; Harold W Koenigsberg; Larry J Sprung; Janine D Flory; Larry J Siever
Journal:  Neuropsychopharmacology       Date:  2010-02-03       Impact factor: 7.853

10.  Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum.

Authors:  Margaret M McClure; Deanna M Barch; Janine D Flory; Philip D Harvey; Larry J Siever
Journal:  J Abnorm Psychol       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.